Tag Archives: h1n1

Flumist with Toxins for Canadians 2010 Flu Season

Canadians To Be Vaccinated With Live H1N1 Virus with MSG For The 2010/11 Flu Season

Dave Mihalovic
Prevent Disease
http://preventdisease.com
September 23, 2010

The Public Health Agency of Canada has once again given their seal of approval for the injection of a dangerous cocktail of toxic chemicals they call a trivalent vaccine. The 2010/11 recipients of AstraZeneca’s FLUMIST will be exposed to several strains of live viruses including H1N1 and H3N2. The vaccine also contains MSG and other known neurotoxins and immunotoxins.

Similar to last year’s Arepanrix Vaccine, FLUMIST was approved without evaluating its safety and effectiveness on a single Canadian.

The vaccines are especially being promoted for children since the nasal spray vaccine can be marketed as less invasive due its intranasal delivery that does not require needles. Ontario’s chief medical officer of health said a non-injectable vaccine is an “attractive option.” The product has been on the U.S. market for the last seven years.

AstraZeneca Canada is currently ensuring that all Canadian pharmacies are making preparations to stock the vaccine this fall. The influenza vaccine will be one of several vaccines to be offered on the Canadian market.

On August 26, 2010, Health Canada issued a Notice of Decision to AstraZeneca Canada for the FLUMIST vaccine.

The FLUMIST Trivalent vaccine product information:

Three Live Viruses:
– Influenza Virus Type A (H1N1);
– Influenza Virus Type A (H3N2); and
– Influenza Virus Type B

Route of Administration:
Intranasal Spray

Dosage Strength:
0.2 mL

Clinically Relevant Nonmedicinal Ingredients
– Gelatin hydrolysate (porcine Type A)
– sucrose
– arginine
– gentamicin

Additional Toxic Ingredients:
– Monobasic potassium phosphate: Immunotoxin
– Arginine hydrochloride: Toxic to lungs and mucous membranes
– Monosodium glutamate: Neurotoxin, Excitotoxin
– Gentamicin: Nephrotoxic

Discussion

There are currently NO clinical trials or results which have validated the long-term safety and efficacy of the FLUMIST vaccine. Regulatory health agencies are refusing to acknowledge this fact or the nature of toxicity levels associated with the FLUMIST and its ingredients. The well documented toxicity evidence for each ingredient presented above are simply ignored.

If you’ll notice, most of the ingredients that are considered non-clinically relevant excipients are ALL TOXIC and yet still injected in every person that receives the vaccine.

No Pharmacokinetic, Carcinogenic or Fertility Studies

One of the most critical elements which defines the toxicity potential of any vaccine are its pharmacokinetic properties. AstraZeneca and Medimmune do not consider the study, analysis or evaluation of the pharmacokinetic properties of any vaccine ingredients or excipients including FLUMIST. This means that the bodily absorption, distribution, metabolism and excretion of ingredients within the vaccine are not known or even considered in safety assessments.

FLUMIST has not been evaluated for its carcinogenic or mutagenic potential or its potential to impair fertility. There have also been NO animal reproduction studies or studies in pregnant or lactating women and it is not known whether FLUMIST is excreted in human milk..

Hospitalizations and Deaths

An increased rate of hospitalizations (for any cause) through 180 days after final vaccination dose of FLUMIST was observed in children 6-11 months of age.

There were eight deaths reported within 180 days of FLUMIST
dosing. Of the 8 deaths, 4 occurred within 42 days after the last dose of FLUMIST. 43 and 180 days after FLUMIST dosing, deaths were due to diarrhea and sepsis, encephalopathy, suffocation, and posterior fossa tumor and malignant hyperthermia.

Adverse Reactions

– Pain
– Redness
– Swelling
– Fatigue
– Headaches
– Arthralgia (joint inflammation)
– Myalgia (muscle inflammation)
– Shivering
– Sweating
– Swollen lymph nodes
– Fever
– Vomiting
– Tingling or numbness of the hands or feet
– Shortness of breath
– Vasculitis (inflammation of the blood vessels)

Serious Adverse Reactions

Congenital, familial and genetic:
– Exacerbation of symptoms of mitochondrial encephalomyopathy (Leigh syndrome)

Immune system:
– Anaphylactic reactions, facial edema and urticaria

Nervous system:
– Guillain-Barré syndrome, Bell’s Palsy

Respiratory, thoracic and mediastinal:
– Epistaxis

Skin and subcutaneous tissue:
– Rash

The information above clearly demonstrates that the Public Health Agency of Canada and Health Canada have no interest in meeting some of the most basic precautions to safeguard the health of Canadians.

Last year, just as flu activity increased across Canada, federal authorities warned Canadians not to buy natural remedies and to strictly confide in the anti-viral drugs and vaccines authorized by Health Canada.

172,000 doses were eventually recalled and withdrawn after serious adverse reactions, notably in the heart and lungs, and hundreds of deaths were reported.

Fresh food that lasts from eFoods Direct (Ad)

Please protect yourself naturally from the flu. Learn what colds and flus really are and use common sense to best of your ability.

Dave Mihalovic is a Naturopathic Doctor who specializes in vaccine research, cancer prevention and a natural approach to treatment.

Advertisements

H1N1 Miscarriage Risk

New evidence that H1N1 vaccine is linked to fetal demise.
http://preventdisease.com/news/10/091410_H1N1_miscarriages_shocking_report.shtml

I had been going on about this last year, such as in the video below. I hate to say that I told you so, but I told you so.

It is stated plainly in the Arepanrix adjuvanted H1N1 vaccine package that the product was associated with miscarriage, birth defects and developmental delays in rats.Nonetheless, our government continues to recommend that pregnant women take the adjuvanted vaccine if flu rates are increasing and they are unable to get the unadjuvanted version at that time. How can our public health officials consider this an acceptable risk/benefit ratio?About 1 in 450 pregnant women who catch influenza will go on to develop complications. According to data from Australian epidemiological surveillance, one in 3800 pregnant women are hospitalized for flu-related complications, but these women had other risk factors such as obesity. The risk of pregnant women dying from flu was found to be about 1/300000.
http://articles.mercola.com/sites/articles/archive/2009/11/03/What-We-Have-Learned-About-the-Great-Swine-Flu-Pandemic.aspx
As of the making of this video on November 16, 2009, there had only been one “H1N1-related” death in a pregnant woman in Canada since the virus first appeared in April 2009, and this woman actually died of blood loss following an emergency C-section done because she was suffering respiratory distress. In other words, the flu was only very loosely connected to a single death. Meanwhile, the vaccine has to date never been tested in pregnant women and is known to have adverse outcomes in the offspring of treated rats. Clinical trials on pregnat women were SUSPENDED because the women developed fever, which is known to affect fetal development. Whether the public health officials are totally incompetent or are being negligent, either way there is a serious problem.
Arepanrix package insert stating risk of m/c, birth defects and developmental delays:
http://www.hc-sc.gc.ca/dhp-mps/prodpharma/legislation/interimorders-arretesurgence/prodinfo-vaccin-eng.php
“Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, acute and repeated dose toxicity, local tolerance, female fertility, embryo-fetal and postnatal toxicity up to the end of the lactation period.

BUT THE DATA CONTRADICTS THE ABOVE CONCLUSION. FROM THE SAME INSERT:

“Two reproductive studies were conducted with AS03-adjuvanted H5N1 antigen and evaluated the effect on embryo-fetal and peri-and post-natal development in rats, following intramuscular administration. Although no definite conclusion could be reached, regarding a possible relation to treatment with the H5N1 vaccine and/or the adjuvant AS03, and other findings were considered normal, the following observations deserve to be mentioned: In the first study, there was an increased incidence of fetal malformations with markedly medially thickened/kinked ribs and bent scapula as well as an increased incidence of dilated ureter and delayed neurobehavioral maturation. In the second study, there was an increased incidence of post-implantation loss, and the fetal variation of dilated ureter. Not all findings were observed in both studies, and hence the toxicological significance is uncertain.”

REPORTING SUSPECTED SIDE EFFECTS
To monitor vaccine safety, the Public Health Agency of Canada collects information on serious and unexpected adverse events following vaccination. If you suspect you have had a serious or unexpected event following receipt of a vaccine you may notify the Public Health Agency of Canada:
By toll-free telephone: 1-866-844-0018
By toll-free fax: 1-866-844-5931
By email: caefi@phac-aspc.gc.ca

Canadian Government dosing recommendations:
http://www.phac-aspc.gc.ca/alert-alerte/h1n1/vacc/recommendation-recommandation-eng.php